Bridgewater Associates LP Has $925,000 Position in Henry Schein, Inc. (NASDAQ:HSIC)

Bridgewater Associates LP lowered its holdings in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 77.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,367 shares of the company's stock after selling 45,887 shares during the period. Bridgewater Associates LP's holdings in Henry Schein were worth $925,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Smartleaf Asset Management LLC increased its position in shares of Henry Schein by 23.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 759 shares of the company's stock worth $52,000 after acquiring an additional 143 shares in the last quarter. Guggenheim Capital LLC increased its position in shares of Henry Schein by 2.5% in the fourth quarter. Guggenheim Capital LLC now owns 6,428 shares of the company's stock worth $445,000 after acquiring an additional 159 shares in the last quarter. CIBC Asset Management Inc increased its position in shares of Henry Schein by 1.0% in the fourth quarter. CIBC Asset Management Inc now owns 17,849 shares of the company's stock worth $1,235,000 after acquiring an additional 169 shares in the last quarter. Metis Global Partners LLC increased its position in shares of Henry Schein by 4.7% in the fourth quarter. Metis Global Partners LLC now owns 4,203 shares of the company's stock worth $291,000 after acquiring an additional 187 shares in the last quarter. Finally, Central Pacific Bank Trust Division increased its position in shares of Henry Schein by 2.0% in the fourth quarter. Central Pacific Bank Trust Division now owns 10,200 shares of the company's stock worth $706,000 after acquiring an additional 200 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company's stock.

Henry Schein Stock Performance

Shares of NASDAQ HSIC traded up $0.38 during mid-day trading on Thursday, hitting $65.87. The company had a trading volume of 125,334 shares, compared to its average volume of 1,608,950. The firm has a market cap of $8.07 billion, a P/E ratio of 27.12, a PEG ratio of 2.13 and a beta of 0.84. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. Henry Schein, Inc. has a 12 month low of $60.56 and a 12 month high of $82.49. The business's 50-day simple moving average is $69.66 and its 200-day simple moving average is $71.83.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.23 by ($0.04). The business had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.25 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.66 EPS. As a group, analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HSIC has been the topic of several analyst reports. Jefferies Financial Group lifted their target price on shares of Henry Schein from $77.00 to $80.00 and gave the stock a "hold" rating in a research report on Thursday, January 23rd. Wells Fargo & Company started coverage on shares of Henry Schein in a report on Friday, February 14th. They set an "equal weight" rating and a $80.00 price target for the company. Barrington Research restated an "outperform" rating and set a $90.00 price target on shares of Henry Schein in a report on Wednesday, February 26th. Bank of America upgraded shares of Henry Schein from an "underperform" rating to a "buy" rating and raised their price target for the stock from $69.00 to $84.00 in a report on Monday, January 6th. Finally, UBS Group decreased their price target on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a report on Wednesday, February 26th. Six analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Henry Schein presently has an average rating of "Moderate Buy" and an average price target of $81.10.

Insiders Place Their Bets

In related news, Director Philip A. Laskawy sold 2,604 shares of the firm's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the sale, the director now owns 24,805 shares of the company's stock, valued at $1,762,147.20. This trade represents a 9.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Bradford C. Connett sold 4,036 shares of the firm's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the completion of the sale, the chief executive officer now directly owns 62,688 shares of the company's stock, valued at approximately $4,460,251.20. This represents a 6.05 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company's stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.